Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination Therapies for Nonalcoholic Fatty Liver Disease
Evangelia Makri, Eleftheria Makri, Stergios A. Pοlyzos
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1166-1166
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
Ilias D. Vachliotis, Stergios A. Pοlyzos
Current Obesity Reports (2023) Vol. 12, Iss. 3, pp. 191-206
Open Access | Times Cited: 40
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Dimitrios D. Raptis, Christos S. Mantzoros, Stergios A. Pοlyzos
Therapeutics and Clinical Risk Management (2023) Vol. Volume 19, pp. 77-96
Open Access | Times Cited: 22
Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management
Stergios A. Pοlyzos, Christos S. Mantzoros
Metabolism (2024) Vol. 157, pp. 155936-155936
Closed Access | Times Cited: 9
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Stergios A. Pοlyzos, Giovanni Targher
Current Obesity Reports (2024) Vol. 13, Iss. 2, pp. 242-255
Open Access | Times Cited: 8
Circulating leptin in patients with nonalcoholic fatty liver disease‐related liver fibrosis: a systematic review and a meta‐analysis
Evangelia Makri, Kleo Evripidou, Stergios A. Pοlyzos
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 5, pp. 806-817
Closed Access | Times Cited: 7
Macrophages and the development and progression of non-alcoholic fatty liver disease
Bader Alabdulaali, Fatema Al‐Rashed, Mohammed Al‐Onaizi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Advances in genetic variation in metabolism-related fatty liver disease
Fan Shi, Mei Zhao, Shudan Zheng, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 11
Animal studies on glucagon-like peptide-1 receptor agonists and related polyagonists in nonalcoholic fatty liver disease
Chara Tsiampali, Ilias D. Vachliotis, A. Goulas, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 611-619
Open Access | Times Cited: 3
To do one and to get more: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases
Wen-Ling Lee, Peng‐Hui Wang, Szu‐Ting Yang, et al.
Journal of the Chinese Medical Association (2022)
Open Access | Times Cited: 14
Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease
Evangelia Makri, Konstantinos Xanthopoulos, Panagiotis Mavrommatis-Parasidis, et al.
Endocrine (2024) Vol. 85, Iss. 2, pp. 704-716
Open Access | Times Cited: 2
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review
Kiana Mohammadian, Fatemeh Fakhar, Shayan Keramat, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 797-797
Open Access | Times Cited: 2
Molecular Pharmacology of Vitamin C and Relevance to Health and Obesity—A Narrative Review
Robert Wilson, Yicong Liang, Devesh Kaushal, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7523-7523
Open Access | Times Cited: 2
NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
Omar E Hegazi, Samer O Alalalmeh, Ghala Rashid Humaid Alnuaimi, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 6
Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
Ilias D. Vachliotis, Ioannis Valsamidis, Stergios A. Pοlyzos
Cancers (2023) Vol. 15, Iss. 21, pp. 5306-5306
Open Access | Times Cited: 5
The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis
Myung‐Ho Kim, Subin Ahn, Nayeon Hur, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
Ricardo Amorim, Pedro Soares, Daniel Chavarria, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116723-116723
Open Access | Times Cited: 1
Vitamin E in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Stergios A. Pοlyzos, Jannis Kountouras
Journal of Gastroenterology and Hepatology (2024)
Closed Access | Times Cited: 1
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
Myrsini Orfanidou, Stergios A. Pοlyzos
Medicina (2024) Vol. 61, Iss. 1, pp. 38-38
Open Access | Times Cited: 1
Combination therapies in nonalcoholic fatty liver disease using antidiabetic and disease-specific drugs
Evgenia Koureta
Annals of Gastroenterology (2023)
Open Access | Times Cited: 4
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Chara Tsiampali, Paraskevi Papaioannidou, A. Goulas, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1063-1072
Closed Access | Times Cited: 3
Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target
Yuan Yao, Yunfeng Shen
Open Life Sciences (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Eleftheria Makri, Myrsini Orfanidou, Evangelia Makri, et al.
Journal of Clinical and Experimental Hepatology (2024) Vol. 14, Iss. 3, pp. 101353-101353
Closed Access
Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Evangelia Makri, Eleftheria Makri, A. Goulas, et al.
Annals of Gastroenterology (2024)
Open Access
Page 1 - Next Page

Scroll to top